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Bcl-xL Deamidation Is a Critical Switch
in the Regulation of the Response to DNA Damage
tineoplastic agents selectively induce p53 null tumor cell
apoptosis.
Because they play a central role in the apoptotic pro-
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al., 2000, 2001). Activated Bak and Bax facilitate mito-3 The Siteman Cancer Center
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It has recently been demonstrated that the antiapo-School of Medicine
ptotic Bcl-2 proteins Bcl-2 and Bcl-xL inhibit apoptosisWashington University
by blocking the activity of BH3 domain-only proteins660 South Euclid Avenue, Campus Box 8052
(Cheng et al., 2001). The precise function of the antiapo-Saint Louis, Missouri 63110
ptotic Bcl-2 family members in the response to DNA
damage has yet to be defined, however. Critical unre-
solved issues include the following. (1) Why are thereSummary
proteins that block the activity of BH3 domain-only pro-
teins once they are activated? (2) After DNA damage,The therapeutic value of DNA-damaging antineoplas-
do antiapoptotic Bcl-2 proteins function merely as im-tic agents is dependent upon their ability to induce
mutable buffers of proapoptotic activity or do they ac-tumor cell apoptosis while sparing most normal tis-
tively regulate the apoptotic process? (3) Do the antiapo-sues. Here, we show that a component of the apoptotic
ptotic Bcl-2 family members all share a redundant roleresponse to these agents in several different types of
in the response to DNA damage or do any of them havetumor cells is the deamidation of two asparagines in
a unique function?the unstructured loop of Bcl-xL, and we demonstrate
In addressing these issues, we found that treatment ofthat deamidation of these asparagines imports sus-
several types of tumor cells with DNA-damaging agentsceptibility to apoptosis by disrupting the ability of
induces deamidation of two asparagines in the unstruc-Bcl-xL to block the proapoptotic activity of BH3 do-
tured loop of Bcl-xL. We demonstrate that deamidationmain-only proteins. Conversely, Bcl-xL deamidation is
completely disrupts the antiapoptotic activity of Bcl-xL,actively suppressed in fibroblasts, and suppression of
and that this occurs because it disrupts the ability ofdeamidation is an essential component of their resis-
Bcl-xL to block the proapoptotic activity of BH3 domain-tance to DNA damage-induced apoptosis. Our results
only Bcl-2 proteins. Importantly, we show that Bcl-xLsuggest that the regulation of Bcl-xL deamidation has deamidation is actively suppressed in growth-arresteda critical role in the tumor-specific activity of DNA-
fibroblasts, which is indeed critical for the suppressiondamaging antineoplastic agents.
of cisplatin-induced apoptosis in these cells.
Introduction
Results
DNA-damaging antineoplastic agents are effective be- Rb-Mediated Arrest of Tumor Cells Suppresses
cause they induce tumor cell apoptosis (Schmitt and a DNA-Damaging Antineoplastic Agent-Induced
Lowe, 1999). Most tumor cells lack wild-type p53 activity Modification of Bcl-xL(Evan and Vousden, 2001), and therefore p53-indepen- Some antineoplastic agents damage the DNA of normal
dent signaling pathways must be of primary importance as well as tumor cells, but selectively cause tumor cell
in tumor cell apoptosis. These pathways are presumably apoptosis. Most tumors lack Rb activity; however, Rb
intact in the cells of normal tissue; however, apoptotic is present in all normal tissue (Nevins, 2001), and it is a
signaling is suppressed in many of these cells. For ex- potent antiapoptotic protein (Haas-Kogan et al., 1995).
ample, fibroblasts arrest without undergoing apoptosis Therefore, we considered the possibility that Rb has a
in response to DNA damage (Di Leonardo et al., 1994), role in the tumor cell selectivity of such antineoplastic
and high concentrations of cisplatin-DNA adducts accu- agents.
mulate in many tissues, not just in the malignant tissue, To begin to determine the mechanism by which DNA
during cisplatin treatment (Poirier et al., 1987, 1992; Ter- damage selectively induces tumor cell death, we gener-
heggen et al., 1987), yet cisplatin treatment does not ated a p53 null, Rb null osteosarcoma cell line (SAOS-2)
cause apoptosis in most normal tissue. We sought to in which Rb expression is inducible. Whereas SAOS-2
determine the mechanism by which DNA-damaging an- cells were susceptible to cisplatin-induced apoptosis,
cisplatin-induced apoptosis was blocked by Rb expres-
sion (Figure 1A).6 Correspondence: weintraubs@msnotes.wustl.edu
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Figure 1. Cisplatin Induces an Rb-Suppressible Modification of Bcl-xL
(A) Rb blocks cisplatin-induced death of SAOS-2 cells. Dose response of Rb-inducible SAOS-2 cells. Rb expression was induced by treatment
with doxycycline (dox) for 36 hr prior to cisplatin treatment.
(B) Rb does not block cisplatin-DNA adduct formation in SAOS-2 cells. Left: immunostaining for Rb. Rb is expressed in almost all of the cells
in the Rb-inducible SAOS-2 cell line treated with dox. Right: cisplatin-DNA adduct formation was detected using an antibody specific for
cisplatin-DNA adducts (Tilby et al., 1991). Rb expression was induced as in (A).
(C) Rb blocks cisplatin-induced cytochrome c release. Rb expression was induced as in (A). Cells were then treated with 5 M cisplatin for
96 hr and cytochrome c localization was assessed. DN-caspase-9 was stably expressed in these cells to facilitate visualization of cytochrome
c release.
(D) Cisplatin treatment induces a modification of Bcl-xL that is not detected in Bcl-2. Immunoblot of Bcl-xL and Bcl-2 from untreated and
cisplatin-treated (5 M) SAOS-2 cells.
(E) The modification of Bcl-xL correlates temporally with cisplatin-induced cell death. SAOS-2 cells were treated with 5 M cisplatin.
(F) The cisplatin-induced modification of Bcl-xL is not a consequence of apoptosis. BIMEL-inducible SAOS-2 cells were induced with dox.
Immunoblots of BIM, Bcl-xL, and caspase-9 cleavage. An immunoblot of a lysate from cisplatin-treated cells is shown for comparison.
(G) Overexpressed Bcl-xL undergoes the same modification as endogenous Bcl-xL. Bcl-xL was overexpressed in SAOS-2 cells, and then the
cells were treated with cisplatin. Immunoblot of Bcl-xL. 10-fold more lysate from the untransfected cells was used to facilitate the comparison
with overexpressed Bcl-xL.
(H) Rb blocks the cisplatin-induced modification of Bcl-xL. Immunoblots of Rb and Bcl-xL from Rb-inducible SAOS-2 cells treated with cisplatin
(5 M) as indicated. Rb expression was induced as in (A).
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We next sought to identify cisplatin-induced proapo-
ptotic signals that are suppressed by expression of Rb.
Rb expression had no affect on cisplatin-DNA adduct
formation (Figure 1B), and we have found that induction
of Rb expression in SAOS-2 cells even as late as 12 hr
after the cells were irradiated efficiently protected them
from  radiation-induced apoptosis (data not shown). We
next found that Rb expression blocks cisplatin-induced
mitochondrial cytochrome c release (Figure 1C). Based
on these findings, we hypothesized that Rb suppresses
a proapoptotic signal(s) that is either parallel to or down-
stream of DNA damage, but upstream of mitochondrial
cytochrome c release during the cisplatin-induced apo-
ptotic response in SAOS-2 cells.
Figure 2. DNA-Damaging Agents Induce the Same Rb-Suppress-Because mitochondrial cytochrome c release is regu-
ible Modification of Bcl-xL in p53 Null, Rb Null Tumor Cell Lines andlated in large part by Bcl-2 proteins (Gross et al., 1999), Primary Ovarian Cancer Cells
we examined Bcl-2 family members during cisplatin-
(A) Cisplatin induces the same modification of Bcl-xL in tumor cellinduced apoptosis. Cisplatin induced a modification of lines and primary ovarian cancer cells. Immunoblot of the Bcl-xL
Bcl-xL; in contrast, Bcl-2 appeared to be unaffected by from an osteosarcoma cell line (SAOS-2), a cervical cancer cell line
cisplatin treatment (Figure 1D). The Bcl-xL modification (C33A), bladder cancer cell line (HTB-9), and ovarian cancer cells
that were treated with cisplatin (5 M) as indicated.correlated temporally with death (Figure 1E). These find-
(B) Different DNA-damaging agents induce the same Rb-suppress-ings suggested that Bcl-xL has a role in the regulation
ible modification of Bcl-xL. Immunoblot of Bcl-xL from Rb-inducibleof the SAOS-2 cell response to cisplatin.
SAOS-2 cells treated with cisplatin (5 M), etoposide (10 M), or 
We then sought to rule out the possibility that the radiation (20 Gy). Rb expression was induced with dox for 36 hr
modification of Bcl-xL was simply an effect of apoptosis. prior to treatment with the DNA-damaging agents.
We found that the Bcl-xL modification that occurs during
cisplatin-induced apoptosis does not occur during BIM-
induced apoptosis (Figure 1F) or apoptosis induced by of disparate origin. This modification is not the result of
either E2F-1 overexpression or treatment with stauro- mitochondrial dysfunction or apoptosis, and suppres-
sporine (data not shown). Therefore, apoptosis per se sion of the Bcl-xL modification by Rb correlates with the
does not cause the Bcl-xL modification. More impor- ability of Rb to inhibit apoptosis.
tantly, even though overexpression of Bcl-xL blocks cis-
platin-induced mitochondrial cytochrome c release and DNA-Damaging Agents Induce
apoptosis (data not shown), we found that overex- Deamidation of Bcl-xLpressed Bcl-xL is modified in cisplatin-treated cells in Paclitaxel induces phosphorylation of Bcl-xL and Bcl-2,the same manner as the endogenous Bcl-xL (Figure 1G), and phosphorylation alters their migration during SDS-
indicating that the modification occurs upstream of the
PAGE (Poruchynsky et al., 1998; Yamamoto et al., 1999).
mitochondria. These findings ruled out the possibility
We compared the Bcl-xL and Bcl-2 from SAOS-2 cellsthat the cisplatin-induced modification of Bcl-xL is merely that were treated with DNA-damaging agents or pacli-a result of mitochondrial dysfunction or apoptosis.
taxel. The migration of Bcl-xL isolated from cells treatedBecause Rb blocks cisplatin-induced apoptosis in
with DNA-damaging agents differed significantly fromSAOS-2 cells, we examined the effect of Rb expression
that of the Bcl-xL isolated from paclitaxel-treated cellson the cisplatin-induced modification of Bcl-xL. Expres-
(Figure 3A). Furthermore, phosphatase treatment com-sion of Rb suppressed the modification of Bcl-xL (Figure
pletely reverses the paclitaxel-induced modification of1H). Interestingly, neither p21CIP1 nor p27KIP1 had a similar
Bcl-xL (Poruchynsky et al., 1998); however, phosphataseeffect (see Supplemental Data at http://www.cell.com/
treatment had no effect on the DNA damage-inducedcgi/content/full/111/1/51/DC1). Therefore, we thought that
modification of Bcl-xL (data not shown). Finally, althoughsuppression of the Bcl-xL modification could be a com-
the paclitaxel-induced modification of Bcl-2 was detect-ponent of the antiapoptotic activity of Rb. We address
able, there was no detectable modification of the Bcl-2 inthis possibility below.
cells that had been treated with DNA-damaging agentsWe then assessed the effect of cisplatin treatment on
(Figure 3A). These findings indicate that the modificationendogenous Bcl-xL in two additional p53 null, Rb null
of Bcl-xL induced by DNA-damaging agents is differentcell lines and in ovarian cancer cells that were freshly
from that induced by paclitaxel.isolated from malignant ascites. Cisplatin induced the
Bacterially synthesized rat Bcl-xL undergoes deami-same modification of Bcl-xL in these cells (Figure 2A).
dation in vitro (Aritomi et al., 1997); however, the signifi-Additionally, Rb blocked cisplatin-induced apoptosis
cance of Bcl-xL deamidation has not been addressed.and the cisplatin-induced modification of Bcl-xL in
Deamidation is a posttranslational modification in whichHTB-9 cells (data not shown), a Rb null, p53 null bladder
asparagines are converted to a mixture of aspartatescancer cell line. Finally, we found that the DNA-damag-
and isoaspartates (Aswad et al., 2000). An asparagineing agents etoposide and  radiation induce the same
is most susceptible to deamidation when it is followedmodification of Bcl-xL as cisplatin, and that Rb sup-
by a glycine in an unstructured region of a protein (Rob-presses the effects of each (Figure 2B). Therefore, sev-
inson and Robinson, 2001). Two such sites are con-eral DNA-damaging agents induce the same Rb-sup-
pressible modification of Bcl-xL in a range of tumor cells served in the nine upper vertebrate Bcl-xL proteins listed
Cell
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Figure 3. DNA Damage Induces Deamidation of Asparagines 52 and 66 of Bcl-xL
(A) DNA-damaging agents and paclitaxel induce different modifications of Bcl-xL. Immunoblots of Bcl-xL and Bcl-2 from SAOS-2 cells treated
with cisplatin (5 M), etoposide (10 M), or paclitaxel (100 nM).
(B) Potential deamidation sites are conserved in Bcl-xL. Asparagine is most susceptible to deamidation when it is followed by glycine in an
unstructured region of a protein. Two such sites are conserved in every upper vertebrate Bcl-xL protein for which the sequence is available.
(C) Cisplatin treatment and incubation in an alkaline buffer seem to induce the same modification of Bcl-xL. Immunoblot analysis of Bcl-xL
and Bcl-2 from SAOS-2 cell lysates that were incubated at pH 7 or pH 9 for the indicated time. An immunoblot of lysates from cisplatin-
treated cells is shown for comparison.
(D) Incubation in an alkaline buffer causes deamidation of the asparagine in a peptide that corresponds to Bcl-xL amino acids 64–68. Top:
the peptide FAVNGA (phenylalanine was added to the N terminus of the Bcl-xL sequence for quantitative analysis by absorption spectroscopy)
was incubated for 24 hr at 37C at the indicated pH and analyzed by reverse-phase HPLC. Bottom: electrospray ionization tandem mass
spectrometric analysis of the new peaks of material observed in the alkaline reaction mixture demonstrated that Asn was converted to Asp
or an isomer of Asp.
(E) Substitution of alanine for the asparagines at the potential deamidation sites blocks the modification of Bcl-xL in both untreated and
cisplatin-treated (5 M) cells (see Results for details).
(F) Constitutively deamidated forms of Bcl-xL migrate in the same position as the modified forms of Bcl-xL when analyzed by SDS-PAGE (see
Results for details).
(G) The alkalinization-induced modification of Bcl-xL occurs at asparagines 52 and 66. Lysates made from SAOS-2 cells transfected with wild-
type Bcl-xL, Bcl-xL (N52A/N66A), Bcl-xL (N52D/N66A), or Bcl-xL (N52D/N66D) were incubated at the indicated pH. Immunoblots of Bcl-xL.
in GenBank (Figure 3B). Therefore, we considered the buffer at neutral pH, we found that the Bcl-xL from a
lysate incubated in the same buffer at alkaline pH mi-possibility that DNA-damaging agents induce the deam-
idation of Bcl-xL. grated in the same pattern as the Bcl-xL from cisplatin-
treated cells (Figure 3C). To explore the basis for theBecause alkaline conditions increase the rate of pro-
tein deamidation (Johnson et al., 1989; Robinson and altered mobility, we incubated a peptide that corre-
sponds to Bcl-xL amino acids 64–68 in similar buffers.Rudd, 1974), we first assessed the endogenous Bcl-xL
from a cell lysate incubated at an alkaline pH. Whereas Tandem mass spectrophotometric analysis demon-
strated that incubation of this peptide in alkaline bufferBcl-xL was unaffected by incubation of the lysate in a
Inactivation of Bcl-xL by Deamidation
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We next assessed the effect of alkaline pH on wild-Table 1. Predicted Deamidation Half-Lives of the Asparagines in
type Bcl-xL, Bcl-xL(N52A/N66A), Bcl-xL(N52D/N66A), andBcl-xL
Bcl-xL(N52D/N66D). After incubation in the alkaline
Asparagine Predicted Deamidation
buffer, the migration of wild-type Bcl-xL was altered asHalf-Life (Relative)
expected, but the migration of the mutant forms was
5 6,050 unaffected (Figure 3G). Because replacement of Bcl-xL
33 64 asparagines 52 and 66 with alanines or aspartates
52 1
blocks the alkaline-induced modification, these results54 405
provided further evidence that the cisplatin-induced66 1
128 36,023 modification of Bcl-xL is deamidation of asparagines 52
136 299 and 66.
175 4,095 Finally, a method for predicting the deamidation rate
185 543 of any asparagine in a protein for which the three-dimen-
The relative predicted deamidation half-lives of the asparagines in sional structure is known was recently published (Rob-
Bcl-xL were calculated using the formula developed by N.E. Rob- inson, 2002). The predicted deamidation half-lives of
inson (Robinson, 2002). The calculations are based on the X-ray Bcl-xL asparagines 52 and 66 are extraordinarily shortstructure of Bcl-xL (Muchmore et al., 1996) and were performed when compared with the other asparagines in Bcl-xLusing the program at http://deamidation.entrewave.com.
(Table 1) and the asparagines in most other proteins
(Robinson, 2002). Thus, the nature of the predicted de-
amidation half-lives of Bcl-xL asparagines 52 and 66
caused deamidation of the asparagine that corresponds serves as corroborative evidence that the cisplatin-
to asparagine 66 of Bcl-xL (Figure 3D). These findings induced modification of Bcl-xL results from deamidation
suggested that the cisplatin-induced modification of of Bcl-xL asparagines 52 and 66.
Bcl-xL is deamidation. When considered together, our results indicate that
We next generated constructs that express forms of these mutant forms of Bcl-xL are essentially the equiva-
human Bcl-xL in which alanines are substituted for the lent of the corresponding forms of Bcl-xL found in un-
two asparagines at the potential deamidation sites treated and cisplatin-treated tumor cells. Indeed, it is
(residues 52 and 66) either individually, in constructs very likely that Bcl-xL(N52D/N66D) is precisely the same
Bcl-xL(N52A) and Bcl-xL(N66A), or together, in construct as its corresponding endogenous form of Bcl-xL.
Bcl-xL(N52A/N66A). We found that replacement of either
asparagine with alanine blocked the formation of the Deamidation Disrupts Bcl-xL Activityslowest migrating form of Bcl-xL and replacement of We compared the antiapoptotic activity of the constitu-
both asparagines blocked the formation of the slowest tively deamidated forms of Bcl-xL with that of wild-typeand intermediate forms of Bcl-xL (Figure 3E). Because Bcl-xL. Whereas wild-type Bcl-xL efficiently blocked cis-these are the forms of Bcl-xL that increase in cells that platin-induced apoptosis in SAOS-2 cells, neither of the
have been treated with DNA-damaging agents, these
constitutively deamidated forms displayed significant
findings suggested that DNA damage induces deamida-
antiapoptotic activity, even though they were expressed
tion of Bcl-xL. at levels exceeding that of the wild-type Bcl-xL (FigureAspartate is one of the major products of asparagine
4A). Therefore, deamidation of asparagines 52 and 66deamidation, and aspartate undergoes spontaneous
disrupts the antiapoptotic activity of Bcl-xL.conversion to the other major asparagine deamidation
The loss of antiapoptotic activity upon deamidationproduct, isoaspartate. However, aspartate and iso-
is not simply due to the removal of the asparagines ataspartate do not spontaneously convert back to aspara-
positions 52 and 66 per se, as it has been demonstratedgine (Aswad et al., 2000). Therefore, we were able to
that deletion of large regions of Bcl-xL that encompassgenerate constructs that express constitutively deami-
these sites actually increases the antiapoptotic activitydated forms of Bcl-xL by substituting aspartates for the
of Bcl-xL (Chang et al., 1997), and we have found thatasparagines.
replacement of asparagines 52 and 66 in Bcl-xL withOne construct expresses a protein in which an aspar-
alanines to block deamidation [Bcl-xL(N52A/N66A)] simi-tate is substituted for asparagine 52 and alanine is sub-
larly increases the antiapoptotic activity of Bcl-xL (datastituted for asparagine 66, Bcl-xL(N52D/N66A)—the
not shown). This indicates that the deamidation prod-equivalent of a Bcl-xL protein that is deamidated at only
ucts at residues 52 and 66 actively disrupt Bcl-xL activity.one of the potential deamidation sites. The second con-
One possible explanation for this is that the introductionstruct expresses a form of Bcl-xL in which aspartates
of negatively charged amino acids at these positionsreplace both asparagine 52 and 66, Bcl-xL(N52D/
alters the tertiary structure of Bcl-xL.N66D)—the equivalent of a Bcl-xL protein that is deami-
It was recently demonstrated that the antiapoptoticdated at both of the potential deamidation sites. When
activity of Bcl-xL is due to its ability to block the proapo-evaluated by SDS-PAGE, the singly deamidated form
ptotic activity of BH3 domain-only proteins, and thatmigrated with the intermediate Bcl-xL band, and the
Bcl-xL must be able to bind the BH3 domain-only pro-Bcl-xL protein that is deamidated at both sites migrated
teins to do so (Cheng et al., 2001). Therefore, we com-in the same position as the slowest migrating form of
pared the ability of the nondeamidated and the constitu-endogenous Bcl-xL (Figure 3F). Because these are the
tively deamidated forms of Bcl-xL to bind to the BH3forms of Bcl-xL that increase in cells treated with DNA-
domain-only protein BIM (O’Connor et al., 1998). Wedamaging agents, these findings provided further evi-
dence that DNA damage induces deamidation of Bcl-xL. found that the nondeamidated form of Bcl-xL binds over-
Cell
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We found that whereas endogenous BIM binds to the
nondeamidated form of Bcl-xL, it fails to bind to Bcl-xL
once the Bcl-xL is deamidated (Figure 4C). Thus, deami-
dation disrupts the antiapoptotic activity of Bcl-xL at
least in part by disrupting the ability of Bcl-xL to block
the proapoptotic activity of BH3 domain-only proteins.
The Antiapoptotic Activity of Rb Is Dependent
upon Bcl-xL in Tumor Cells and Fibroblasts
This work was initiated in an attempt to identify proapo-
ptotic signals or events that are actively suppressed in
the cells of normal tissue. Because Rb is absent or
inactive in most tumors but present in all normal tissue
(Nevins, 2001), we were intrigued by the finding that Rb
expression in tumor cells suppresses the inactivating
deamidation of Bcl-xL (Figures 1H and 2B) and that the
suppression of Bcl-xL deamidation correlates with the
cisplatin resistance afforded by Rb expression in both
SAOS-2 (Figures 1A and 1H) and HTB-9 cells (data not
shown). Therefore, we wanted to determine if suppres-
sion of Bcl-xL deamidation is a component of the anti-
apoptotic activity of Rb.
Because deamidation completely inactivates the anti-
apoptotic function of Bcl-xL, we first sought to determine
the consequences of Bcl-xL inactivation in Rb-arrested
SAOS-2 cells. To do so, we transfected SAOS-2 cells
with Bcl-x antisense (Figure 5A, left) and then arrested
the cells by inducing Rb expression (Figure 5A, middle)
before they were treated with cisplatin. We found that
inhibition of Bcl-xL expression rendered the growth-
arrested cells sensitive to cisplatin (Figure 5A, right).
Therefore, Rb-arrested SAOS-2 cells are dependent
upon the presence of active Bcl-xL to inhibit apoptosis.
The endogenous Rb in fibroblasts inhibits cisplatin-
Figure 4. Deamidation Disrupts the Antiapoptotic Activity of Bcl-xL induced apoptosis. This is indicated by the finding that
(A) Constitutively deamidated forms of Bcl-xL fail to inhibit cisplatin- rb/ MEFs are susceptible to cisplatin-induced apopto-
induced apoptosis. SAOS-2 cells were transfected with expression sis (Knudsen et al., 2000). Because we had found that
vectors for the wild-type or the constitutively deamidated forms of the antiapoptotic effect of Rb is dependent upon theBcl-xL along with an expression vector for CD20 to identify trans-
presence of active Bcl-xL in SAOS-2 cells, we consideredfected cells. Expression of the wild-type and the constitutively dea-
the possibility that the antiapoptotic effect of Rb in fibro-midated forms of Bcl-xL was assessed by immunoblotting.
(B) Deamidation disrupts the interaction between Bcl-xL and the blasts is also dependent upon the presence of active
BH3 domain-only protein BIM. Expression vectors for the form of Bcl-xL. Indeed, we found that inhibition of fibroblast
Bcl-xL that does not become deamidated, Bcl-xL(N52A/N66A), and Bcl-xL expression rendered normal human diploid fibro-
the form of Bcl-xL that is constitutively deamidated, Bcl-xL(N52D/ blasts (NHDFs) susceptible to cisplatin-induced apopto-N66D), were cotransfected in SAOS-2 cells. An expression vector for
sis (Figure 5B).BIM (EE tagged) was transfected as indicated. Immunoprecipitation
To confirm that the increased susceptibility of thewas performed with an EE tag antibody. Bcl-xL forms that were
coimmunoprecipitated with BIM were detected by immunoblotting. fibroblasts was not an artifact of the antisense treat-
The protein levels are decreased in the far left lane because BIM ment, we assessed the cisplatin susceptibility of wild-
induced apoptosis of a portion of the transfected cells. type, bcl-x/, and bcl-x/MEFs. We found that bcl-x/
(C) Deamidation disrupts the interaction between Bcl-xL and endog- MEFs were significantly more susceptible to cisplatinenous BIM. p53/, bcl-x/ MEFs were transfected with expression
treatment than wild-type MEFs (Figure 5C), indicatingvectors for either Bcl-xL (N52A/N66A) or Bcl-xL (N52D/N66D). The
that the innate cisplatin resistance of wild-type fibro-cells were then treated with 5 M cisplatin for 24 hr to induce BIM
expression. Immunoprecipitation was performed with an antibody blasts is dependent upon the presence of active Bcl-xL,
for BIM. Total Bcl-xL, coimmunoprecipitated Bcl-xL, and BIM were just as it is dependent upon the presence of Rb. Further-
detected by immunoblotting. more, we found that the bcl-x/ MEFs were of interme-
diate susceptibility (Figure 5C), which indicates that the
level of active Bcl-xL is a critical determinant of suscepti-expressed BIM more readily than does the deamidated
bility to cisplatin. Because the endogenous Rb in fibro-form (Figure 4B). We then took advantage of our finding
blasts inhibits apoptosis, these findings indicate thatthat BIM is upregulated by cisplatin treatment of p53/
the effectiveness of Rb as an antiapoptotic protein ismouse embryo fibroblasts (MEFs) (Figure 4C) to assess
dependent upon the amount of active Bcl-xL in fibro-the ability of the nondeamidated and the constitutively
deamidated forms of Bcl-xL to bind to endogenous BIM. blasts.
Inactivation of Bcl-xL by Deamidation
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Figure 5. Bcl-xL Is Necessary to Inhibit Cisplatin-Induced Apoptosis of Both Rb-Arrested Tumor Cells and Normal Fibroblasts
(A) The antiapoptotic activity of Rb in SAOS-2 cells is dependent upon the presence of Bcl-xL. Left: Bcl-x antisense inhibits Bcl-xL expression
without affecting expression of Bcl-2. Rb-inducible SAOS-2 cells were treated with Bcl-x antisense, and then Rb expression was induced by
dox for 36 hr. Immunoblot of Bcl-xL and Bcl-2 from these cells. Middle: Rb expression arrests SAOS-2 cells. SAOS-2 cells in which Rb
expression was induced as indicated. Cells were then labeled with BrdU for 8 hr. BrdU uptake was quantitated by flow cytometry. More than
90% of the cells that expressed Rb were in G1 as assessed by propidium iodide staining and flow cytometry (data not shown). Right: Inhibition
of Bcl-xL expression renders Rb-arrested SAOS-2 cells susceptible to cisplatin. SAOS-2 cells were transfected as indicated and then Rb
expression was induced as indicated for 36 hr prior to treatment with cisplatin (5 M).
(B) NHDFs are dependent upon Bcl-xL to maintain their innate resistance to cisplatin. Fibroblasts were transfected with Bcl-x antisense or
control. Cells were treated with cisplatin for 24 hr.
(C) MEFs are dependent upon Bcl-xL to maintain their innate resistance to cisplatin and the resistance correlates with bcl-x gene dosage.
Dose response of bcl-x/, bcl-x/, and bcl-x/ MEFs. Survival was assessed at 48 hr.
Suppression of Bcl-xL Deamidation Is a Critical we examined the Rb and cyclin A of cisplatin-treated
p53/ MEFs. Rb phosphorylation was unchanged andComponent of the Innate Cisplatin
Resistance of Fibroblasts cyclin A expression was not suppressed by cisplatin
treatment (Figure 6A).We had found that an Rb-mediated growth arrest sup-
presses Bcl-xL deamidation in tumor cells (Figure 1H), Because p53 null MEFs fail to activate Rb in response
to treatment with cisplatin (Figure 6A), we thought itso we considered the possibility that Rb might inhibit
fibroblast apoptosis in part because it suppresses de- notable that inactivation of p53 renders NHDFs and
MEFs susceptible to DNA-damaging agents (Figure 5D;amidation of Bcl-xL. Therefore, we sought to determine
the role of Rb in the regulation of deamidation of Bcl-xL Fan et al., 1995; Hawkins et al., 1996) (we note that it
has been reported that wild-type fibroblasts are morein fibroblasts.
Several DNA-damaging agents have been found to sensitive to DNA-damaging agents than p53/ MEFs;
however, the cells used in the study were transformedinduce activation (dephosphorylation) of fibroblast Rb
(Slebos et al., 1994). We wanted to confirm that Rb with the viral oncogene E1a [Lowe et al., 1993]). We
hypothesized that p53/ fibroblasts are susceptible tois active in cisplatin-treated MEFs. Rb rapidly became
dephosphorylated upon cisplatin treatment (Figure 6A). cisplatin-induced apoptosis, at least in part, because
the lack of Rb activation in these cells would be permis-Cyclin A expression is downregulated in response to
DNA damage in an Rb-dependent manner (Knudsen et sive for Bcl-xL deamidation in the same manner that the
lack of Rb activation is permissive for expression ofal., 1999). Cyclin A was downregulated by cisplatin treat-
ment, confirming that Rb is active in cisplatin-treated cyclin A in cisplatin-treated p53/ MEFs.
Indeed, whereas cisplatin treatment had no effect onMEFs (Figure 6A). Because DNA-damaging agents fail
to activate Rb in cells lacking p53 (Slebos et al., 1994), the Bcl-xL in wild-type MEFs, the Bcl-xL from cisplatin-
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Figure 6. Suppression of Bcl-xL Deamidation Is Necessary to Inhibit Cisplatin-Induced Apoptosis in Fibroblasts
(A) Rb is activated in a p53-dependent manner by cisplatin. MEFs were treated with cisplatin (10 M) for the indicated time. The Rb in the
MEFs was activated by cisplatin treatment, as indicated by the fact that it became dephosphorylated and the finding that expression of cyclin
A was downregulated. These changes did not occur in p53/ MEFs. The decreased levels of Rb in the cisplatin-treated p53/ MEFs is likely
to be due to caspase cleavage (Tan and Wang, 1998).
(B) Loss of p53 renders MEFs susceptible to cisplatin. Dose response of p53/ and wild-type MEFs. Survival was assessed at 96 hr.
(C) Loss of p53 renders Bcl-xL susceptible to cisplatin-induced deamidation. Top: immunoblot of Bcl-xL from wild-type (wt) MEFs, p53/
MEFs, and SAOS-2 cells treated with cisplatin (5 M) as indicated. Bottom: Bcl-xL deamidation is not a consequence of apoptosis in fibroblasts.
Immunoblot of Bcl-xL and cleaved caspase 9 from cisplatin-treated bcl-x/ MEFs. Nearly all of the cells had died by 72 hr (data not shown).
(D) Olomoucine suppresses Bcl-xL deamidation and renders p53/ MEFs resistant to cisplatin. Top: immunoblot of Bcl-xL from p53/ MEFs
treated with olomoucine and cisplatin as indicated. Bottom: dose response of p53/ MEFs treated with cisplatin and olomoucine as indicated.
Cells were maintained in olomoucine for 24 hr prior to and during cisplatin treatment.
(E) The olomoucine-induced cisplatin resistance of p53/ MEFs is dependent upon active Bcl-xL. Dose response of p53/, bcl-x/ MEFs
treated with olomoucine and cisplatin as indicated. Cells were maintained in olomoucine for 24 hr prior to and during cisplatin treatment.
treated p53/ MEFs migrated in precisely the same p21CIP1; hence, in p53/ MEFs, the failure to activate
Rb in response to DNA damage is due to the lack ofpattern as the Bcl-xL from susceptible cisplatin-treated
human tumor cells (Figure 6C). This was not an effect of increased p21CIP1 expression (Dulic et al., 1994; Harper
et al., 1993, 1995). Therefore, we assessed the effect ofapoptosis because the Bcl-xL in bcl-x/ MEFs remains
unperturbed during cisplatin-induced apoptosis (Figure cdk inhibition on the cisplatin susceptibility of p53/
MEFs by treating them with the cdk inhibitor olomou-6C). These results indicate that the Bcl-xL in p53/MEFs
is susceptible to inactivation by deamidation. In Rb- cine. Strikingly, olomoucine rendered the p53/ MEFs
as resistant to cisplatin-induced apoptosis as wild-typearrested SAOS-2 cells and fibroblasts, we found that
active Bcl-xL is a critical component of the resistance MEFs (Figure 6D), and this correlated with the suppres-
sion of Bcl-xL deamidation (Figure 6D). To determine ifto DNA-damaging agents (Figures 5A–5C). We therefore
sought to determine if the maintenance of Bcl-xL activity suppression of Bcl-xL deamidation is necessary for the
protective effect of the olomoucine on the p53/ MEFs,by the suppression of deamidation is required for resis-
tance to cisplatin-induced apoptosis in fibroblasts. we assessed the effect of olomoucine on the cisplatin
sensitivity of p53/ MEFs that lacked Bcl-xL (p53/,p53 causes Rb dephosphorylation by inducing ex-
pression of the cyclin-dependent kinase (cdk) inhibitor bcl-x/ MEFs). Whereas olomoucine rendered p53/
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MEFs as resistant to cisplatin as wild-type MEFs, olo-
moucine failed to confer the same level of resistance to
the p53/, bcl-x/ MEFs as it did to p53/ MEFs (Fig-
ure 6E). Therefore, if Bcl-xL is inactivated, olomoucine
is ineffective in blocking cisplatin-induced apoptosis of
MEFs that lack p53. Because deamidation of Bcl-xL re-
sults in the inactivation of Bcl-xL (Figure 4A), these re-
sults indicated that suppression of Bcl-xL deamidation
is critical for the suppression of cisplatin-induced apo-
ptosis in fibroblasts.
Suppression of Bcl-xL Deamidation Keeps BH3
Domain-Only Protein Activity in Check
It is notable that our experiments using Bcl-x antisense-
treated and bcl-x/ fibroblasts indicate that inactivation
of Bcl-xL only confers susceptibility to cisplatin-induced
apoptosis—cisplatin must activate a second proapo-
ptotic signal(s) before fibroblast apoptosis occurs.
Therefore, it is notable that DNA damage in fibroblasts
results in the upregulation of expression of the proapo-
ptotic BH3 domain-only proteins NOXA and PUMA (Na-
kano and Vousden, 2001; Oda et al., 2000; Yu et al.,
2001), yet fibroblasts growth arrest without undergoing
apoptosis in response to DNA damage (Di Leonardo et
al., 1994). We hypothesized that the upregulation of BH3
domain-only protein expression is the second proapo-
ptotic signal, and that functional Bcl-xL is required to
suppress their proapoptotic activity for fibroblasts to
maintain resistance to apoptosis. Therefore, we exam-
ined Bcl-xL regulation of NOXA activity during the fibro-
blast response to cisplatin.
We first established that NOXA is upregulated by a
concentration of cisplatin that does not normally induce
apoptosis of NHDFs (Figure 7A). We then examined the Figure 7. Bcl-xL Keeps BH3 Domain-Only Protein Activity in Check
effects of cisplatin on NHDFs that were transfected with (A) NOXA is upregulated in NHDFs by a concentration of cisplatin
(10 M) that does not induce apoptosis. Immunoblot of NOXA fromBcl-x antisense alone or together with NOXA antisense.
NHDFs treated as indicated.As we had found previously, inhibition of Bcl-xL expres-
(B) Bcl-xL suppresses the proapoptotic activity of NOXA in NHDFs.sion rendered the cells susceptible to cisplatin-induced
Top: immunoblots of Bcl-xL and NOXA from NHDFs treated withapoptosis (Figure 7B). Because we had found that NOXA
antisense as indicated. Immunoblot of Bcl-xL is from untreated cells;
is upregulated upon treatment with cisplatin, this sug- immunoblot of NOXA is from cisplatin-treated (10 M) cells. Bottom:
gested that functional Bcl-xL is required for the suppres- NHDFs were treated with antisense and cisplatin (10 M) as indi-
cated. Plus sign indicates cells treated with indicated antisense.sion of proapoptotic BH3 domain-only protein activity.
Minus sign indicates cells treated with indicated scrambled control.Indeed, inactivation of NOXA markedly decreased the
cisplatin susceptibility of the Bcl-x antisense-treated
cells (Figure 7B), thereby confirming that Bcl-xL sup-
presses the proapoptotic activity of NOXA. We note that fact that deamidation is of significance to the cell has
NOXA antisense would not be expected to completely never been firmly established. Because it is a relatively
block the apoptotic response because at least one other slow process, it has been proposed that deamidation
BH3 domain-only protein, PUMA, is upregulated by functions as a molecular timer of biological events (Rob-
DNA-damaging agents in fibroblasts (Nakano and Vous- inson and Robinson, 2001). Hence, in respect to the
den, 2001; Yu et al., 2001). These results indicate that regulation of DNA damage-induced apoptosis, Bcl-xL
in fibroblasts, Bcl-xL deamidation must be suppressed deamidation may serve as a chronometric buffer, af-
to maintain resistance to apoptosis because Bcl-xL ac- fording the cell time to reverse low-level genotoxic
tivity is necessary to suppress the proapoptotic activity stress-induced events.
of BH3 domain-only proteins once their expression is In addition to its tumor-suppressor activity, Rb is a
upregulated by DNA damage. potent antiapoptotic protein—loss of Rb in normal fibro-
blasts confers sensitivity to DNA-damaging agents (Al-
masan et al., 1995; Knudsen et al., 2000), and reintroduc-Discussion
tion of Rb into Rb null tumor confers resistance to these
agents (Haas-Kogan et al., 1995). Hence, we reasonedWe show here that deamidation plays a critical role in
a signal transduction pathway. Although it has been that Rb must suppress proapoptotic signals. We found
that Rb suppresses the inactivating deamidation ofdemonstrated that deamidation increases protein turn-
over (Flatmark, 1966; Robinson and Rudd, 1974), the Bcl-xL, and indeed, our findings indicate that the anti-
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in pSFFV-Bcl-xL by converting the codon for asparagine (AAT) toapoptotic activity of Rb is dependent upon the ability
either alanine (GCT) or aspartate (GAT) using QuikChange (Stra-of Rb to suppress Bcl-xL deamidation. Finally, our data
tagene).suggest that the inactivation of Rb increases the suscep-
tibility of tumor cells to DNA-damaging agents in part
Cell Culture and Transfectionsbecause inactivation of Rb is permissive for Bcl-xL de-
SAOS-2 (ATCC HTB-85), C33A (ATCC HTB-31), MRC-5 fibroblastsamidation.
(ATCC CCC-171), and MEFs were maintained in DMEM with 10%
In response to DNA damage, BH3 domain-only pro- FBS. HTB-9 (ATCC HTB-9) cells were maintained in RPMI-1640 with
teins are upregulated in fibroblasts (Nakano and Vous- 10% FBS. p53/ mice were a generous gift from L. Donehower.
den, 2001; Oda et al., 2000; Yu et al., 2001); however, Rb-inducible and BimEL-inducible cells were generated using T-REx
(Invitrogen). The Rb-inducible cells were stably transfected withfibroblasts growth arrest without undergoing apoptosis
pCDNA3-Flag-DN-caspase-9 for the experiment depicted in Figurein response to DNA damage (Di Leonardo et al., 1994).
1C. SAOS-2 cells and p53/, bcl-x/ MEFs were transfected withIt has been unclear how the proapoptotic activity of the
calcium phosphate. For survival assays, cells were cotransfected
BH3 domain-only proteins is suppressed in fibroblasts. with the indicated Bcl-xL plasmid and a CD20 expression vector.
Our results suggest a mechanism in which the proapo- Cells were treated with cisplatin for 96 hr (SAOS-2 cells) unless
ptotic activity of BH3 domain-only proteins is upregu- otherwise indicated, 48 hr (ovarian cancer cells and MEFs), or 24
hr (antisense experiments); 10 M etoposide for 96 hr; 20 Gy lated by DNA damage in cells regardless of whether or
radiation and harvested after 96 hr; or 100 nM paclitaxel for 36not the cell is destined to undergo apoptosis. In fibro-
hr unless otherwise indicated. 50 M olomoucine was used whenblasts, Bcl-xL deamidation is suppressed, and it must
indicated. Survival was quantified by flow cytometry using the Live/
be suppressed to prevent cisplatin-induced apoptosis. Dead kit (Molecular Probes). Cells were labeled with an anti-CD20
In these cells, the proapoptotic activity of the BH3 do- antibody (Pharmingen) as indicated. For alkalinization experiments,
main-only proteins is kept in check by Bcl-xL and other cells were lysed in buffers containing 20 mM sodium phosphate
and 0.2% Triton X-100 at the indicated pH and incubated at 37C.antiapoptotic Bcl-2 family members. However, in cells
such as the p53/ MEFs and the tumor cells we studied,
Bcl-xL is inactivated by deamidation in response to DNA Antisense Treatment
damage, and inactivation of Bcl-xL is sufficient to allow Bcl-x antisense 5-CTACGCTTTCCACGCACAGT-3 and control
5-CTCCGATGTCCCCTCAAAGT-3 (Taylor et al., 1999) were usedBH3 domain-only proteins to initiate the final stages
at 100 nM in SAOS-2 cells and 200 nM in fibroblasts. NOXA antisenseof apoptosis. We note that we have not excluded the
and control (Calbiochem) were used at 50 nM. Oligonucleotidespossibility that other antiapoptotic Bcl-2 family mem-
were transfected with Cytofectin GSV (Glen Research).
bers are also inactivated in response to DNA damage,
but, as we have demonstrated, inactivation of Bcl-xL
Immunoblottingis sufficient to allow the apoptotic process to go to
The following antibodies were used: anti-Bcl-x (B22630) and anti-completion.
Bcl-2 (B46620) from Transduction Laboratories, anti-Bim (AAP-330)
That Bcl-xL serves a unique role in the response to and anti-mouse caspase-9 (AAM-139E) from Stressgen, anti-NOXA
DNA-damaging agents is consistent with recent findings (IMG-349) from Imgenex, anti-human caspase-9 (9502) from NEB,
anti-cyclin A (H-432) from Santa Cruz, and anti-pRb (14001A) fromdemonstrating a correlation between Bcl-xL expression
PharMingen.and resistance to antineoplastic treatment (Amundson
et al., 2000). When the 60 cell lines of the National Cancer
Institute’s Anticancer Drug Screen (NCI-ADS) were as- Immunoprecipitation
SAOS-2 cells were transfected with pSFFV-Bcl-xL(N52A/N66A) andsessed for a correlation between expression of a number
pSFFV-Bcl-xL(N52D/N66D) with pEF-EE-BimEL. Cells were lysed inof cancer-related genes and resistance to chemother-
50 mM HEPES (pH 7.0), 250 mM NaCl, 1 mM EDTA, 0.2% NP-40,apy, the strongest correlation between gene expression
and Complete Protease Inhibitor (Roche). Lysates were incubated
and resistance to a panel of standard chemotherapy with 1 g anti-EE antibody (MMS-115P) from Covance Research
agents was for Bcl-xL. The correlation was stronger than Products prebound to 20 l Protein G Dynabeads (Dynal).
the positive correlation with cytotoxicity that the NCI- For immunoprecipitation of endogenous BIM, p53/, bcl-x/
MEFs were transfected with pCDNA3-Bcl-xL(N52A/N66A) orADS had reported for p53. Indeed, the authors referred
pCDNA3-Bcl-xL(N52D/N66D) and treated with 5 M cisplatin 48 hrto the correlation as “striking.” The importance of Bcl-xL
after transfection. Immunoprecipitation was performed with anti-in resistance to chemotherapy was further underscored
BIM antibody (Ab-1) Oncogene.
by the finding of the same study that Bcl-2 and Bax
levels have no correlation whatsoever with the degree
Immunofluorescence Stainingof cellular sensitivity to chemotherapeutic agents. Our
DNA adducts were detected using the ICR4 antibody (a gift fromfinding that resistance correlates with bcl-x gene dosage
Michael Tilby) and the TSA system (PerkinElmer Life Sciences). Cells
in MEFs suggests that Bcl-xL truly has a functional role were fixed in 4% paraformaldehyde, permeabilized in PBS with 0.2%
in the resistance to antineoplastic therapy, i.e., it is not Triton X-100, blocked in TNB blocking buffer, and treated with
just a marker for another cellular characteristic that im- DNaseI in TNB buffer with 20 mM MgCl2 for 1 hr. The cells were then
incubated with ICR4 in TNB buffer, and then an immunofluorescenceparts resistance.
signal was generated. Anti-cytochrome c (556432 PharMingen) and
anti-HA (3F10 Roche) were used to detect cytochrome c and in-
Experimental Procedures duced Rb, respectively.
Plasmids
pSGL5-HA-Rb (Sellers et al., 1998), pSFFV-Bcl-xL (Yang et al., 1995), Peptide Analysis
The peptide FAVNGA (100 M) was incubated for 24 hr at 37C atpEF-EE-BimEL (O’Connor et al., 1998), pCDNA3-Flag-DN-caspase-9
(Duan et al., 1996), and pCMV-CD20 (van den Heuvel and Harlow, the indicated pH in 20 mM sodium phosphate. HPLC (Fu et al., 2002)
and mass spectrometric analysis (Fu et al., 2001) were performed1993) were generous gifts from W. Kaelin, S. Korsmeyer, A. Strasser,
V. Dixit, and S. van den Heuvel, respectively. Mutations were made as previously described.
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